Prostate cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PSMA 273
• AR 16
• TP53 2
• PARP 13
• PTEN 4
• AKT 1
• BRCA2 7
• BRCA1 9
• STAT3 0
• PI3K 2
• PD-L1 6
• mTOR 1
• PD-1 13
• EZH2 7
• MYC 1
• B7-H3 8
• EGFR 2
• CTNNB1 1
• JNK 0
• ERK 0
• HIF-1 0
• VEGF 2
• BCL-2 0
• MAPK 0
• AMPK 0
• CDK4/6 4
• HER2 6
• NRF2 0
• FAK 0
• PPAR 0
• YAP 0
• IL-6 0
• STING 0
• COX-2 0
• CTLA-4 0
• DLL3 6
• GLP-1 1
• GPX4 0
• HSP90 0
• ATM 1
• HDAC 0
• IL-15 4
• METTL3 1
• BRD4 0
• HER3 2
• JAK 1
• CXCR4 0
• TROP2 3
• CD47 1
• IGF1R 0
• IL-1 0
• MET 1
• PALB2 4
• RB1 0
• TNF 0
• APOE 0
• FGFR 1
• KRAS 0
• MDM2 0
• MEK 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• ALLCDC NCCDPHP · U48

  Optimal survey questions for prostate cancer screening and shared decision-making

  New York University School of Medicine· New York, United States· US$443,904 awarded in fiscal year 2025· until Sept 2029

• ALLCDC NCCDPHP · U48

  Developing and Evaluating Computable Phenotypes to Identify Active Surveillance in Prostate Cancer Using Electronic Health Record Data

  Univ of Massachusetts Med Sch Worcester· Worcester, United States· US$399,303 awarded in fiscal year 2025· until Sept 2028

• NIH NCI · R37

  Targeting Lactylation of Critical Drivers in Neuroendocrine Prostate Cancer for Therapy

  University of Kentucky· Lexington, United States· US$453,367 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R43

  De Novo Minibinder Radiotheranostics for Targeted Treatment of Prostate Cancer

  Vesto Therapeutics, Inc· Seattle, United States· US$400,000 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R42

  Dual Acting Bone Defenders for Inhibiting Cancer Mediated Bone Destruction

  Bonestrong Therapeutics Inc.· Portland, United States· US$400,000 awarded in fiscal year 2026· until Aug 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting stress signaling pathways to enhance prostate cancer immunotherapy (IMMSTRESS)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €202,125· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Circulating Tumor Cell-informed RADioresponse Assessment from heme-axis signatuRes (CTC-RADAR)

  Koc University· Istanbul, Türkiye· EU contribution €398,612· until Dec 2029· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €796,590· until Dec 2030· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploitation of bioorthogonal click-to-release chemistry for precision cancer therapy (click-to-cure)

  Kobenhavns Universitet· Kobenhavn, Denmark· EU contribution €247,553· until Dec 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Proteoform-Resolved Lateral Flow Immunoassay with Antibody Mimics and Engineered Release for Precise Prostate Cancer Diagnosis (PRIME)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €260,348· until Sept 2028

10 of 919 running projects, newest first. Listed amounts together: US$580.4m + €116.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

  NCT06287463· Deciphera Pharmaceuticals, LLC· Updated 5 Mar 2026

  “Trial terminated due to a business decision, not based on any safety concerns.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 42
• Organoids 15
• Mendelian Randomization Analysis 39
• CRISPR-Cas Systems 15
• Gene Expression Profiling 154
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 32
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 125
• Magnetic Resonance Imaging 465
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 276
• Genome-Wide Association Study 62

• Estimated lifetime harms and benefits of continuing biennial prostate cancer screening in older men by comorbidity group.

  Cancer, Nov 2026

• Biomarker use in the prostate cancer screening pathway: Maps of the evidence.

  Cancer, Nov 2026

• Slice-based YOLO-SAM hybrid prompting framework for automatic medical image segmentation.

  PLoS One, Nov 2026

• Real-world performance of pelvic MRI and abdominopelvic CT for nodal staging in higher-risk prostate cancer and the incremental clinical value of CT.

  World J Urol, Nov 2026

• External Validation of Existing Nomograms on Indian Prostate Biopsy Data.

  Int J Urol, Nov 2026

• Risk-adapted MRI Protocols for the Detection of Clinically Significant Prostate Cancer.

  Radiol Imaging Cancer, Nov 2026

• Magnetic Resonance Imaging Findings and Prostate-Specific Antigen Density-Based Risk Stratification for Deferring a Separate Preoperative Biopsy in Candidates for Holmium Laser Enucleation of the Prostate.

  Int J Urol, Nov 2026

• Validation and diagnostic accuracy of fractal dimension as a biomarker for grading prostate cancer using data from clinical routine.

  Br J Radiol, Nov 2026

• Dosimetric impact of baseline shift plan in a magnetic resonance linear accelerator according to target motion and plan characteristics.

  J Appl Clin Med Phys, Nov 2026

• Early Detection of Prostate Cancer: Advances in Screening, Biomarkers, and Imaging Strategies.

  Curr Oncol Rep, Oct 2026

See which targets of this disease your abstract mentions, and go to the people working on them.